Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025JCO oncology advances.Open Access

Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJonathan M. LoreeACAntonio Caycedo‐MarulandaYHYanmei Huang

Discussion

Loading...

Member takes

Overview

Observational analysis revealed circulating tumor DNA detects molecular residual disease in patients, suggesting its potential role in treatment guidance.

Key Points

  • ctDNA was found in 24.5% of patients prior to chemotherapy, indicating a link to clinical stage.
  • The detection rate of ctDNA post-chemotherapy dropped to 6.7%, emphasizing its utility in treatment response assessment.
  • Neoadjuvant chemotherapy included fluorouracil and oxaliplatin, followed by total mesorectal excision if no response occurred.
  • This study suggests integrating ctDNA as a decision aid in clinical practice for managing early-stage rectal cancer.

Cite This Study

Loree et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9d8https://doi.org/10.1200/oa-25-00055
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy2025
  2. 2Circulating Tumor DNA Longitudinal Analysis During Total Neoadjuvant Therapy and Non-operative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial2025
  3. 3Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer2025
  4. 4290. OPTIMIZING ESOPHAGEAL CANCER TREATMENT: PERSONALIZED CTDNA IMPROVES RESIDUAL DISEASE DETECTION AFTER NEOADJUVANT CHEMORADIOTHERAPY AND GUIDES ADAPTIVE ADJUVANT IMMUNOTHERAPY2025 · 1 citations
  5. 5ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma2025